BCAX · Bicara Therapeutics Inc.
$24.70
+0.12 (+0.49%)
At close · Aug 26
Market Cap
$1.64B
Shares
66.17M
Bicara Therapeutics Inc. Earnings Call Transcripts
Quarterly earnings calls for Bicara Therapeutics Inc. (BCAX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-11
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Confident tone
Pivotal Phase III FORTIFY-HN01 study
Commercial readiness and launch preparation
Colorectal cancer signal-seeking study
Diluted EPS
$-0.82
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Confident tone
Clinical data and ASCO presentation
Competitive landscape dynamics
Leadership transition (CMO change)
Diluted EPS
$-0.93
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-30
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
Confident tone
Breakthrough Therapy Designation and regulatory momentum
Clinical data – durability and depth of response
Interim analysis and overall survival endpoint
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Bicara Therapeutics Inc. (BCAX) Q3 2025 Earnings Call
Diluted EPS
$-0.67
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Bicara Therapeutics Inc. (BCAX) Q2 2025 Earnings Call
Diluted EPS
$-0.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Bicara Therapeutics Inc. (BCAX) Q1 2025 Earnings Call
Diluted EPS
$-0.68
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Bicara Therapeutics Inc. (BCAX) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Bicara Therapeutics Inc. (BCAX) Q3 2024 Earnings Call
Diluted EPS
$-1.60
Audio
Transcript
Slides
8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts
CIK
2023658
CUSIP
055477103
13F (30d)
161 filings
160 filers
Visit website
Investor relations